AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18332269 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment (40 mg/d for 6 weeks)
Number of subjects: 922
Study 18332796 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated estradiol levels in nonsurvivors (16 pg/mL vs. 35 pg/mL, p < 0.001)
Number of subjects: 991
Study 18332796 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol as a predictor of death
Number of subjects: 991
Study 18332796 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol as a marker of injury severity
Number of subjects: 991
Study 18332882 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women (n=51)
Number of subjects: 156
Study 18332882 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal controls
Number of subjects: 156
Study 18332882 — intervention group
Group type: EXPERIMENTAL
Intervention: All women
Number of subjects: 156
Study 18332882 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who became postmenopausal
Number of subjects: 156
Study 18332882 — intervention group
Group type: EXPERIMENTAL
Intervention: Women 3-4 years before menopause
Number of subjects: 156
Study 18334033 — intervention group
Group type: EXPERIMENTAL
Intervention: DAB/IL2 (12 microg/kg; four daily doses; 21 day cycles)
Number of subjects: 16
Study 18334537 — intervention group
Group type: EXPERIMENTAL
Intervention: PET scanning in early stage HD patients
Number of subjects: 31
Study 18334676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg daily with dose escalation up to 25 mg daily
Number of subjects: 20
Study 18334676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide in patients with 11q or 17p deletion
Number of subjects: 20
Study 18334676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide in patients with unmutated V(H)
Number of subjects: 20
Study 18334676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide in patients with fludarabine-refractory disease
Number of subjects: 20
Study 18334676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide treatment
Number of subjects: 20
Study 18337339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent live-attenuated dengue vaccine administered on Days 0 and 180
Number of subjects: 7
Study 18337339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent live-attenuated dengue vaccine
Number of subjects: 7
Study 18339636 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir/lamivudine
Number of subjects: 35
Study 18342684 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable everolimus-eluting stent (BVS)
Number of subjects: 30
Study 18346162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine
Number of subjects: 0
Study 18346162 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 18346516 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta (1 mg/kg) infused intravenously every 2 weeks for 48 weeks
Number of subjects: 16
Study 18346516 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase beta treatment
Number of subjects: 16
Study 18348596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES) administered for 6 weeks using the Alpha-Stim Stress Control System at 0.5-Hz frequency and 300-muA intensity.
Number of subjects: 12
Study 18348596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES)
Number of subjects: 12
Study 18349311 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y microspheres, median activity 1.83 GBq, dose 112.8 Gy, mean number of treatments 1.6
Number of subjects: 137
Study 18349311 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y microspheres
Number of subjects: 137
Study 18353175 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring with nurse-led telephone support
Number of subjects: 360
Study 18353175 — intervention group
Group type: COMPARATOR
Intervention: Usual care (blood pressure monitoring by their practice)
Number of subjects: 360
Study 18355417 — intervention group
Group type: EXPERIMENTAL
Intervention: Group presentation of study results
Number of subjects: 0
Study 18356759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (14 sessions of weekly or intensive family-based)
Number of subjects: 96
Study 18356759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 96
Study 18359949 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of calcium content of foods
Number of subjects: 718
Study 18359949 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy toward consuming calcium-rich foods
Number of subjects: 718
Study 18359949 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity self-efficacy
Number of subjects: 718
Study 18359949 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity outcome expectations
Number of subjects: 718
Study 18359949 — intervention group
Group type: EXPERIMENTAL
Intervention: Family encouragement to do physical activity
Number of subjects: 718
Study 18359949 — intervention group
Group type: EXPERIMENTAL
Intervention: Friend engagement in physical activity
Number of subjects: 718
Study 18359949 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in sports teams
Number of subjects: 718
Study 18363467 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum estradiol concentration at 48 hours
Number of subjects: 0
Study 18363467 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum estradiol cut-point of 50 pg/mL
Number of subjects: 0
Study 18363467 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 0
Study 18366712 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure dressing
Number of subjects: 108
Study 18366712 — intervention group
Group type: COMPARATOR
Intervention: Non-pressure dressing
Number of subjects: 108
Study 18373143 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR-based clinician prompt
Number of subjects: 794
Study 18373143 — intervention group
Group type: COMPARATOR
Intervention: Wait-room-based case-finding
Number of subjects: 794
Study 18376001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0
Study 18376001 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 18378607 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg/d for 24 months
Number of subjects: 507
Study 18378608 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg QD
Number of subjects: 7950
Study 18378608 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID
Number of subjects: 7950
Study 18378608 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg BID
Number of subjects: 7950
Study 18378608 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (all doses combined)
Number of subjects: 7950
Study 18379729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg, gemcitabine 1,000 mg/m2 at FDR infusion, cisplatin 20 mg/m2 on days 1 and 15 of a 28-day cycle
Number of subjects: 52
Study 18379729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg, gemcitabine 1,000 mg/m2 at FDR infusion, cisplatin 20 mg/m2
Number of subjects: 52
Study 18379729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing regimen
Number of subjects: 52
Study 18379729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 52
Study 18383194 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional power-based stopping thresholds
Number of subjects: 0
Study 18383194 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical aids for statistical risks
Number of subjects: 0
Study 18384244 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized assessment by physicians prior to screening for the study
Number of subjects: 65
Study 18384244 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient units
Number of subjects: 65
Study 18384244 — intervention group
Group type: COMPARATOR
Intervention: Emergency rooms
Number of subjects: 65
Study 18385168 — intervention group
Group type: EXPERIMENTAL
Intervention: Maugeri Respiratory Failure (MRF-28) questionnaire
Number of subjects: 72
Study 18385168 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe Respiratory Insufficiency (SRI) questionnaire
Number of subjects: 72
Study 18385168 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Respiratory Questionnaire (CRQ)
Number of subjects: 72
Study 18385168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 72
Study 18385168 — intervention group
Group type: EXPERIMENTAL
Intervention: Groningen Activity and Restriction Scale
Number of subjects: 72
Study 18385168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnoea indexes
Number of subjects: 72
Study 18385760 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologically confirmed PIN
Number of subjects: 263
Study 18385760 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologically confirmed AIN
Number of subjects: 263
Study 18385760 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk-alpha-HPV-DNA in PIN lesions
Number of subjects: 263
Study 18385760 — intervention group
Group type: EXPERIMENTAL
Intervention: p16(INK4a) Expression
Number of subjects: 263
Study 18387185 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote pacemaker interrogation using the Medtronic CareLink(R) Network (CareLink)
Number of subjects: 980
Study 18387185 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of transtelephonic monitoring (TTM)
Number of subjects: 980
Study 18387850 — intervention group
Group type: EXPERIMENTAL
Intervention: CERE-120 (adeno-associated virus serotype 2-neurturin) at a dose of 1.3x10(11) vg/patient
Number of subjects: 12
Study 18387850 — intervention group
Group type: EXPERIMENTAL
Intervention: CERE-120 (adeno-associated virus serotype 2-neurturin) at a dose of 5.4x10(11) vg/patient
Number of subjects: 12
Study 18387850 — intervention group
Group type: EXPERIMENTAL
Intervention: CERE-120 (adeno-associated virus serotype 2-neurturin)
Number of subjects: 12
Study 18388178 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD measured by flow cytometry in peripheral blood at day 8
Number of subjects: 2143
Study 18388178 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD measured by flow cytometry in end-induction (day 29) marrow
Number of subjects: 2143
Study 18388178 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD at end of consolidation
Number of subjects: 2143
Study 18388178 — intervention group
Group type: EXPERIMENTAL
Intervention: All favorable risk factors including absence of days 8 and 29 MRD
Number of subjects: 2143
Study 18390837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 300 mg
Number of subjects: 40
Study 18390837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 500 mg
Number of subjects: 40
Study 18390837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 700 mg
Number of subjects: 40
Study 18390837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 1000 mg
Number of subjects: 40
Study 18390837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (all doses)
Number of subjects: 40
Study 18391140 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 206
Study 18391140 — intervention group
Group type: COMPARATOR
Intervention: Psychiatric control group
Number of subjects: 206
Study 18391140 — intervention group
Group type: COMPARATOR
Intervention: Healthy reference group
Number of subjects: 206
Study 18391140 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported sleep
Number of subjects: 206
Study 18391430 — intervention group
Group type: EXPERIMENTAL
Intervention: Seneca Valley Virus-001 (SVV-001)
Number of subjects: 0
Study 18391430 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystallization of SVV-001
Number of subjects: 0
Study 18394819 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) to a dose of 6,000 cGy (Stage IA) or 6,600 cGy (Stage IB), given in three equal fractions.
Number of subjects: 70
Study 18394819 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 70
Study 18398457 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin daily
Number of subjects: 41
Study 18398457 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin daily with IFN-beta comedication
Number of subjects: 41
Study 18398457 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin daily without IFN-beta comedication
Number of subjects: 41
Study 18398457 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 41
Study 18399724 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 106
Study 18399724 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 106
Study 18399724 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 106
Study 18399724 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 106
Study 18399724 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic medications
Number of subjects: 106
Study 18399724 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 106
Study 18400084 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Disability Index Questionnaire (NDI)
Number of subjects: 221
Study 18400084 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Outcome Measure (COM)
Number of subjects: 221
Study 18400084 — intervention group
Group type: EXPERIMENTAL
Intervention: Northwick Pain Questionnaire (NPQ)
Number of subjects: 221
Study 18401605 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-field PERG measurements (P50, N95, P50+N95 amplitudes)
Number of subjects: 26
Study 18401605 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal and temporal hemifield PERG studies
Number of subjects: 26
Study 18401605 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak times and N95:P50 amplitude ratios
Number of subjects: 26
Study 18401605 — intervention group
Group type: COMPARATOR
Intervention: Nasal and temporal hemifield PERG values
Number of subjects: 26
Study 18401605 — intervention group
Group type: EXPERIMENTAL
Intervention: Best discriminating parameters
Number of subjects: 26
Study 18401605 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient PERG amplitude measurements
Number of subjects: 26
Study 18401605 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemifield stimulation PERG parameters
Number of subjects: 26
Study 18402897 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C levels after admission
Number of subjects: 507
Study 18402897 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol levels
Number of subjects: 507
Study 18402897 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol levels
Number of subjects: 507
Study 18402897 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting triglyceride levels
Number of subjects: 507
Study 18402903 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial deformation imaging
Number of subjects: 53
Study 18402903 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced cardiac magnetic resonance imaging (ceMRI)
Number of subjects: 53
Study 18405390 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (200 UI/day)
Number of subjects: 100
Study 18405390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18407271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous proton pump inhibitors (PPI)
Number of subjects: 631
Study 18407271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study 18413173 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate fitness group (MF, n=46)
Number of subjects: 92
Study 18413173 — intervention group
Group type: COMPARATOR
Intervention: Low fitness group (LF, n=46)
Number of subjects: 92
Study 18413173 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cardiorespiratory fitness
Number of subjects: 92
Study 18415830 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS)
Number of subjects: 257
Study 18415830 — intervention group
Group type: EXPERIMENTAL
Intervention: Center for Epidemiologic Studies Depression Scale (CESD-SF)
Number of subjects: 257
Study 18415830 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale Short Form (GDS-SF)
Number of subjects: 257
Study 18416598 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment at a dosage of 1 g/m(2)
Number of subjects: 293
Study 18416598 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression assessment in primary ALL cells
Number of subjects: 293
Study 18416841 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-report survey interviews
Number of subjects: 525
Study 18416841 — intervention group
Group type: COMPARATOR
Intervention: Medical record documentation
Number of subjects: 525
Study 18419786 — intervention group
Group type: EXPERIMENTAL
Intervention: Acylated ghrelin
Number of subjects: 0
Study 18419879 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg orally for 29 days
Number of subjects: 19
Study 18419879 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 19
Study 18420097 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol esters (PSE) supplementation
Number of subjects: 82
Study 18420097 — intervention group
Group type: EXPERIMENTAL
Intervention: Western-type diet (WTD) with PSE
Number of subjects: 82
Study 18420097 — intervention group
Group type: EXPERIMENTAL
Intervention: PSE-supplemented margarine
Number of subjects: 82
Study 18420097 — intervention group
Group type: COMPARATOR
Intervention: Western-type diet (WTD)
Number of subjects: 82
Study 18420097 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe (EZE)
Number of subjects: 82
Study 18420500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care (mechanical ventilation)
Number of subjects: 4446
Study 18421079 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital images
Number of subjects: 761
Study 18421079 — intervention group
Group type: COMPARATOR
Intervention: Film images
Number of subjects: 761
Study 18421079 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized images
Number of subjects: 761
Study 18423103 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5/10 mg/day
Number of subjects: 440
Study 18426260 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 11
Study 18426260 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 11
Study 18426260 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 11
Study 18426260 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram and Escitalopram
Number of subjects: 11
Study 18426260 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum (12 weeks)
Number of subjects: 11
Study 18426988 — intervention group
Group type: EXPERIMENTAL
Intervention: AMD3100 (240 mug/kg by subcutaneous injection)
Number of subjects: 25
Study 18426988 — intervention group
Group type: EXPERIMENTAL
Intervention: AMD3100
Number of subjects: 25
Study 18436082 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol, 0.5 microg, twice weekly for 12 weeks
Number of subjects: 10
Study 18436120 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-improvement program
Number of subjects: 8608
Study 18436120 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medications
Number of subjects: 8608
Study 18436120 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of care measures
Number of subjects: 8608
Study 18436120 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge instructions and smoking cessation counseling
Number of subjects: 8608
Study 18436120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital length of stay
Number of subjects: 8608
Study 18436554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline therapy (in combination with other antibiotics in 28 patients)
Number of subjects: 42
Study 18436554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline therapy
Number of subjects: 42
Study 18437127 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan or Atenolol-based treatments
Number of subjects: 0
Study 18438111 — intervention group
Group type: EXPERIMENTAL
Intervention: APPEAR procedure for neoplasia or trauma
Number of subjects: 14
Study 18438111 — intervention group
Group type: EXPERIMENTAL
Intervention: APPEAR procedure for ulcerative colitis
Number of subjects: 14
Study 18438111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileostomy closure
Number of subjects: 14
Study 18438111 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectal physiological testing following perineal dissection
Number of subjects: 14
Study 18438111 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient sexual dysfunction
Number of subjects: 14
Study 18438111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileostomy reversal
Number of subjects: 14
Study 18438123 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Scanning (EIS)
Number of subjects: 216
Study 18439279 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning programme
Number of subjects: 3632
Study 18441370 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal delivery of AAV2.hRPE65v2
Number of subjects: 3
Study 18441371 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal injections of recombinant adeno-associated virus vector 2/2 expressing RPE65 cDNA
Number of subjects: 3
Study 18443195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 0
Study 18443195 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 18443260 — intervention group
Group type: EXPERIMENTAL
Intervention: Precipitating factors identified at admission (e.g., pneumonia, ischemia, worsening renal function)
Number of subjects: 48612
Study 18443260 — intervention group
Group type: EXPERIMENTAL
Intervention: Precipitating factors identified at admission (e.g., ischemia, worsening renal function)
Number of subjects: 48612
Study 18443260 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertension as a precipitating factor
Number of subjects: 48612